SG11201804787UA - Human immunodeficiency virus neutralizing antibodies - Google Patents
Human immunodeficiency virus neutralizing antibodiesInfo
- Publication number
- SG11201804787UA SG11201804787UA SG11201804787UA SG11201804787UA SG11201804787UA SG 11201804787U A SG11201804787U A SG 11201804787UA SG 11201804787U A SG11201804787U A SG 11201804787UA SG 11201804787U A SG11201804787U A SG 11201804787UA SG 11201804787U A SG11201804787U A SG 11201804787UA
- Authority
- SG
- Singapore
- Prior art keywords
- foster city
- international
- rule
- gilead sciences
- lakeside drive
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 3
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 1111111111111111111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/106346 A2 WIPO I PCT (43) International Publication Date 22 June 2017 (22.06.2017) (51) International Patent Classification: Not classified (21) International Application Number: PCT/US2016/066658 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KR KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (22) International Filing Date: 14 December 2016 (14.12.2016) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62267652 15 December 2015 (15.12.2015) US (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US). (72) Inventors: BALAKRISHNAN, Mini; c/o Gilead Sci- ences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). CARR, Brian A.; do Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). CORBIN, John; 5816 Mendocino Avenue, Oakland, CA 94618 (US). PACE, Craig S.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). THOMSEN, Nathan D.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US) ZHANG, Xue; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). (74) Agents: DAMMANN, Yu-Ming et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, as to applicant's entitlement to apply for and be granted a patent (Rule 4.170) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 1063 46 A2 (54) Title: HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES (57) : The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceut- ical compositions, and methods of use thereof
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267652P | 2015-12-15 | 2015-12-15 | |
PCT/US2016/066658 WO2017106346A2 (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804787UA true SG11201804787UA (en) | 2018-07-30 |
Family
ID=58737847
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108793TA SG10202108793TA (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
SG11201804787UA SG11201804787UA (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108793TA SG10202108793TA (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Country Status (37)
Country | Link |
---|---|
US (3) | US10239935B2 (en) |
EP (2) | EP3390441B1 (en) |
JP (4) | JP6732915B2 (en) |
KR (1) | KR102165120B1 (en) |
CN (2) | CN109311967B (en) |
AR (1) | AR106991A1 (en) |
AU (3) | AU2016370591C1 (en) |
BR (1) | BR112018012164A2 (en) |
CA (1) | CA3008442C (en) |
CL (1) | CL2018001587A1 (en) |
CO (1) | CO2018006050A2 (en) |
CR (1) | CR20180321A (en) |
CU (1) | CU20180062A7 (en) |
CY (1) | CY1124756T1 (en) |
DK (1) | DK3390441T3 (en) |
DO (2) | DOP2018000146A (en) |
EA (2) | EA202091898A1 (en) |
EC (1) | ECSP18045028A (en) |
ES (1) | ES2897756T3 (en) |
HU (1) | HUE056243T2 (en) |
IL (1) | IL259832B (en) |
LT (1) | LT3390441T (en) |
MA (1) | MA44077A (en) |
MX (2) | MX2018007288A (en) |
MY (2) | MY186414A (en) |
NZ (1) | NZ743713A (en) |
PE (1) | PE20181451A1 (en) |
PH (1) | PH12018501281A1 (en) |
PL (1) | PL3390441T3 (en) |
SA (1) | SA518391778B1 (en) |
SG (2) | SG10202108793TA (en) |
SI (1) | SI3390441T1 (en) |
SV (1) | SV2018005710A (en) |
TW (2) | TWI735491B (en) |
UA (1) | UA125819C2 (en) |
WO (1) | WO2017106346A2 (en) |
ZA (1) | ZA201803783B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
BR112017013858A2 (en) | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hydroxycytidine and related antiviral derivatives and uses |
AU2016347058B2 (en) | 2015-10-25 | 2023-11-09 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection |
EA202091898A1 (en) | 2015-12-15 | 2021-06-22 | Джилид Сайэнс, Инк. | ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS |
DK3443006T5 (en) | 2016-04-13 | 2023-11-06 | Sanofi Sa | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS |
SG11201808911SA (en) | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
CA3065328C (en) | 2017-06-21 | 2023-08-15 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
MX2020005392A (en) | 2017-12-07 | 2020-12-07 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto. |
CN111741973A (en) * | 2017-12-19 | 2020-10-02 | 洛克菲勒大学 | Human IgG Fc domain variants with improved effector function |
AU2019226034A1 (en) * | 2018-02-21 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 Env and their use |
EP3797118A4 (en) * | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
MX2020013621A (en) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Hiv treatment compositions and methods. |
EP3817819A1 (en) | 2018-07-03 | 2021-05-12 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
EP3849607A4 (en) * | 2018-09-13 | 2022-06-22 | Children's National Medical Center | Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same |
WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
CA3121004A1 (en) * | 2018-12-19 | 2020-06-25 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
EP3908664A4 (en) * | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
TW202231277A (en) * | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
CN114641488A (en) * | 2019-07-08 | 2022-06-17 | 加州理工学院 | anti-HIV vaccine antibodies with reduced polyreactivity |
CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
KR20220156884A (en) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021207635A1 (en) * | 2020-04-09 | 2021-10-14 | The George Washington University | Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof |
AU2021333577A1 (en) | 2020-08-25 | 2023-03-30 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
WO2022272275A1 (en) * | 2021-06-25 | 2022-12-29 | Janssen Vaccines & Prevention B.V. | Combinations of vaccines and neutralizing antibodies for treating human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
AU2022399845A1 (en) | 2021-12-03 | 2024-05-23 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230212148A1 (en) | 2021-12-03 | 2023-07-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202400172A (en) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (en) | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | Method for producing magnetic iron oxide/dextran complex |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
PT81498B (en) | 1984-11-23 | 1987-12-30 | Schering Ag | METHOD FOR PREPARING COMPOSITIONS FOR DIAGNOSTICS CONTAINING MAGNETIC PARTICLES |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
DK1628685T3 (en) | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antiviral phosphonate analogues |
HUE024962T2 (en) | 2004-02-06 | 2016-02-29 | Univ Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
US7871991B2 (en) | 2004-07-27 | 2011-01-18 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
WO2006050219A2 (en) | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US20100056898A1 (en) | 2005-06-13 | 2010-03-04 | Mckenna David R | Objective Methods of Estimating Age of Animals and Carcasses |
TW201402124A (en) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 8-substituted benzoazepines as toll-like receptor modulators |
TWI382019B (en) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | Aminodiazepines as toll-like receptor modulators |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
JP4783325B2 (en) | 2007-04-09 | 2011-09-28 | 株式会社神戸製鋼所 | High temperature exhaust gas treatment method |
PT2170888E (en) | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purine derivatives and their use as modulators of toll-like receptor 7 |
JP5285709B2 (en) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | Human immunodeficiency virus replication inhibitor |
DK2313111T3 (en) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-like receptor agonist formulations and their use |
WO2010056898A2 (en) | 2008-11-12 | 2010-05-20 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory b cells |
CN102272134B (en) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Modulators of toll-like receptors |
EP2398496B1 (en) | 2009-02-20 | 2015-08-05 | International AIDS Vaccine Initiative | Vesicular stomatitis virus vectors encoding hiv env epitopes |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
BR112012003757A2 (en) | 2009-08-18 | 2020-08-11 | Ventirx Pharmaceuticals, Inc. | benzoazepines replaced as bell-fold receptor modulators |
US8524702B2 (en) | 2009-08-18 | 2013-09-03 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
CN103209963A (en) | 2010-07-02 | 2013-07-17 | 吉里德科学公司 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds |
CN103140474A (en) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | Napht- 2 -ylacetic acid derivatives to treat aids |
CN102374226A (en) | 2010-08-06 | 2012-03-14 | 深圳富泰宏精密工业有限公司 | Sleeve, hinge structure, and portable electronic device using hinge structure |
WO2012030904A2 (en) | 2010-08-31 | 2012-03-08 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
MX2013003632A (en) | 2010-09-28 | 2013-05-20 | Fujitsu Ltd | Method and base station, user equipment and system for activating coexistence work mode. |
JP5951615B2 (en) | 2010-10-01 | 2016-07-13 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. | Therapeutic use and combination therapy of TLR agonists |
CA2812787A1 (en) | 2010-10-01 | 2012-04-05 | Robert Hershberg | Methods for the treatment of allergic diseases |
KR101416437B1 (en) | 2010-11-03 | 2014-07-10 | 한국전자통신연구원 | Wavelength tunable external cavity laser generating device |
EP2640720B1 (en) | 2010-11-18 | 2018-10-17 | Yale University, Inc. | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
PL2663550T3 (en) | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
MX348935B (en) | 2011-01-12 | 2017-07-03 | Ventirx Pharmaceuticals Inc | Substituted benzoazepines as toll-like receptor modulators. |
WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
ME03782B (en) | 2011-04-08 | 2021-04-20 | Janssen Sciences Ireland Unlimited Co | Pyrimidine derivatives for the treatment of viral infections |
BR112013027096A2 (en) | 2011-04-21 | 2016-12-27 | Gilead Sciences Inc | benzothiazole compounds and their pharmaceutical use |
JP6050329B2 (en) | 2011-05-18 | 2016-12-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Quinazoline derivatives for treating viral infections and other diseases |
JP6205354B2 (en) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Compounds for the treatment of HIV |
CN102863512B (en) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | Antiviral compound |
EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
KR20190007106A (en) | 2011-12-21 | 2019-01-21 | 노비라 테라퓨틱스, 인코포레이티드 | Hepatitis b antiviral agents |
MY169159A (en) | 2012-02-08 | 2019-02-19 | Janssen R&D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
MD20140063A2 (en) | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Benzothiazol-6-il acetic acid derivatives and their use for treating an HIV infection |
US11149069B2 (en) | 2012-08-03 | 2021-10-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
US9284304B2 (en) | 2012-08-10 | 2016-03-15 | Janssen Sciences Ireland Uc | Substituted pyrimidines as toll-like receptor modulators |
ES2670513T3 (en) | 2012-10-10 | 2018-05-30 | Janssen Sciences Ireland Uc | Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases |
MX361585B (en) | 2012-11-16 | 2018-12-11 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections. |
CN111303152B (en) | 2012-12-21 | 2023-04-11 | 吉利德科学公司 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CN104903323A (en) | 2012-12-27 | 2015-09-09 | 日本烟草产业株式会社 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor |
US10066238B2 (en) * | 2013-02-11 | 2018-09-04 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
UA118751C2 (en) | 2013-02-21 | 2019-03-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | 2-aminopyrimidine derivatives for the treatment of viral infections |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
JP2017501986A (en) | 2013-12-02 | 2017-01-19 | アーロン ダイアモンド エイズ リサーチ センター | Potency and breadth of improved HIV-1 neutralizing antibodies by cell receptor anchoring using bispecific antibodies with native composition |
AU2015287773B2 (en) * | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
PL3321265T3 (en) | 2015-03-04 | 2020-11-16 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors |
EA202091898A1 (en) | 2015-12-15 | 2021-06-22 | Джилид Сайэнс, Инк. | ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS |
-
2016
- 2016-12-14 EA EA202091898A patent/EA202091898A1/en unknown
- 2016-12-14 TW TW105141486A patent/TWI735491B/en active
- 2016-12-14 ES ES16867376T patent/ES2897756T3/en active Active
- 2016-12-14 CA CA3008442A patent/CA3008442C/en active Active
- 2016-12-14 CU CUP2018000062A patent/CU20180062A7/en unknown
- 2016-12-14 MY MYPI2018702243A patent/MY186414A/en unknown
- 2016-12-14 US US15/379,157 patent/US10239935B2/en active Active
- 2016-12-14 BR BR112018012164A patent/BR112018012164A2/en active Search and Examination
- 2016-12-14 AU AU2016370591A patent/AU2016370591C1/en active Active
- 2016-12-14 EA EA201891186A patent/EA201891186A1/en unknown
- 2016-12-14 CN CN201680079823.5A patent/CN109311967B/en active Active
- 2016-12-14 SG SG10202108793TA patent/SG10202108793TA/en unknown
- 2016-12-14 CN CN202210281565.6A patent/CN114848812A/en active Pending
- 2016-12-14 EP EP16867376.2A patent/EP3390441B1/en active Active
- 2016-12-14 SI SI201631372T patent/SI3390441T1/en unknown
- 2016-12-14 UA UAA201806361A patent/UA125819C2/en unknown
- 2016-12-14 WO PCT/US2016/066658 patent/WO2017106346A2/en active Application Filing
- 2016-12-14 AR ARP160103833A patent/AR106991A1/en unknown
- 2016-12-14 TW TW110130315A patent/TWI814056B/en active
- 2016-12-14 MY MYPI2021003644A patent/MY196200A/en unknown
- 2016-12-14 HU HUE16867376A patent/HUE056243T2/en unknown
- 2016-12-14 DK DK16867376.2T patent/DK3390441T3/en active
- 2016-12-14 JP JP2018530831A patent/JP6732915B2/en active Active
- 2016-12-14 PE PE2018001115A patent/PE20181451A1/en unknown
- 2016-12-14 MX MX2018007288A patent/MX2018007288A/en unknown
- 2016-12-14 CR CR20180321A patent/CR20180321A/en unknown
- 2016-12-14 KR KR1020187019806A patent/KR102165120B1/en active IP Right Grant
- 2016-12-14 NZ NZ743713A patent/NZ743713A/en unknown
- 2016-12-14 LT LTEPPCT/US2016/066658T patent/LT3390441T/en unknown
- 2016-12-14 PL PL16867376T patent/PL3390441T3/en unknown
- 2016-12-14 SG SG11201804787UA patent/SG11201804787UA/en unknown
- 2016-12-14 EP EP21192543.3A patent/EP3992206A1/en active Pending
- 2016-12-14 MA MA044077A patent/MA44077A/en unknown
-
2018
- 2018-06-05 IL IL259832A patent/IL259832B/en unknown
- 2018-06-07 ZA ZA2018/03783A patent/ZA201803783B/en unknown
- 2018-06-11 SA SA518391778A patent/SA518391778B1/en unknown
- 2018-06-13 DO DO2018000146A patent/DOP2018000146A/en unknown
- 2018-06-13 CL CL2018001587A patent/CL2018001587A1/en unknown
- 2018-06-13 SV SV2018005710A patent/SV2018005710A/en unknown
- 2018-06-13 CO CONC2018/0006050A patent/CO2018006050A2/en unknown
- 2018-06-13 EC ECIEPI201845028A patent/ECSP18045028A/en unknown
- 2018-06-14 PH PH12018501281A patent/PH12018501281A1/en unknown
- 2018-06-14 MX MX2022013524A patent/MX2022013524A/en unknown
-
2019
- 2019-02-12 US US16/273,753 patent/US10882898B2/en active Active
- 2019-12-05 AU AU2019275625A patent/AU2019275625B2/en active Active
-
2020
- 2020-05-14 JP JP2020085079A patent/JP6936361B2/en active Active
- 2020-12-03 US US17/110,876 patent/US11655285B2/en active Active
-
2021
- 2021-01-29 DO DO2021000022A patent/DOP2021000022A/en unknown
- 2021-08-26 JP JP2021137876A patent/JP7126594B2/en active Active
- 2021-11-04 AU AU2021261910A patent/AU2021261910B2/en active Active
- 2021-11-10 CY CY20211100980T patent/CY1124756T1/en unknown
-
2022
- 2022-08-16 JP JP2022129584A patent/JP2022163192A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression |